Pharmaceutical preparations and methods for inhibiting tumors

A polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:

• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, said polypeptide analog being capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).

A polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:

• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, said polypeptide analog being capable of inhibiting the growth of a tumor.

The use of a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:

• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO:
• 6 (polypeptide 76-94) and mixture(s) thereof, for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).

The use of a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:

• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO:
• 6 (polypeptide 76-94) and mixture(s) thereof, for inhibiting the growth of a tumor.

The use of a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:

• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5 for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).

The use of a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:

• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5 for inhibiting the growth of a tumor.

A method for treating a patient with prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:

• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO:
• 6 (polypeptide 76-94) and mixtures thereof.

A method for treating a patient with a tumor, the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:

• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO:
• 6 (polypeptide 76-94) and mixtures thereof.

A method for treating a patient with prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:

• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, said polypeptide analog being capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).

A method for treating a patient with a tumor, the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:

• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, said polypeptide analog being capable of inhibiting the growth a tumor.

A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:

• a) a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:
• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (Polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), the polypeptide as set forth in SEQ ID NO:
• 6 (Polypeptide 76-94) and mixture(s) thereof, and;
• b) an anticancer drug.

A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:

• a) a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:
• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (Polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), the polypeptide as set forth in SEQ ID NO:
• 6 (Polypeptide 76-94) and mixture(s) thereof, and;
• b) a pharmaceutically acceptable carrier.

A pharmaceutical composition comprising:

• a) A polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:
• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), the polypeptide as set forth in SEQ ID NO:
• 6 (polypeptide 76-94) and mixture(s) thereof in a therapeutically effective amount, and;
• b) an anticancer drug in a therapeutically effective amount.

A pharmaceutical composition comprising:

• a) a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:
• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), the polypeptide as set forth in SEQ ID NO:
• 6 (polypeptide 76-94) and mixture(s) thereof in a therapeutically effective amount, and;
• b) a pharmaceutically acceptable carrier.

A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:

• a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and mixture(s) thereof, and;
• b) an anticancer drug.

A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:

• a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and mixture(s) thereof, and;
• a) a pharmaceutically acceptable carrier.

A pharmaceutical composition comprising:

• a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5 and mixture(s) thereof in a therapeutically effective amount, and;
• b) an anticancer drug in a therapeutically effective amount.

A pharmaceutical composition comprising:

• a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5 and mixture(s) thereof in a therapeutically effective amount, and;
• b) a pharmaceutically acceptable carrier.

A method for treating patients with a disease characterized by elevated levels of FSH comprising administering a pharmaceutical composition in an appropriate dosage form, the pharmaceutical composition comprising a polypeptide selected from the group consisting of rHuPSP94 as set forth SEQ ID NO:

• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4, the polypeptide as set forth in SEQ ID NO:
• 5, and the polypeptide as set forth in SEQ ID NO:
• 6, and a pharmaceutically acceptable carrier.

A method for treating patients with a disease characterized by elevated levels of FSH comprising administering a pharmaceutical composition in an appropriate dosage form, the pharmaceutical composition comprising a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:

• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, apolypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5 and mixture(s) thereof, and a pharmaceutically acceptable carrier, in a human dose.

The use of a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:

• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO:
• 6 (polypeptide 76-94) and mixture(s) thereof, for treating patients with a disease characterized by elevated levels of FSH.

The use of a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:

• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5 and mixture(s) thereof, for treating patients with a disease characterized by elevated levels of FSH.

The use of a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO:

• 2, the decapeptide as set forth in SEQ ID NO:
• 3, the polypeptide as set forth in SEQ ID NO:
• 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO:
• 5 (PCK3145), the polypeptide as set forth in SEQ ID NO:
• 6 (polypeptide 76-94) and mixtures thereof for the manufacture of a medicament for the therapeutic treatment of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia (BPH) or a disease characterized by elevated levels of FSH.

The use of a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO:

• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO:
• 2, of SEQ ID NO:
• 3, of SEQ ID NO:
• 4, of SEQ ID NO:
• 5, or of SEQ ID NO:
• 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
• 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 59 to SEQ ID NO:
• 88, a polypeptide analog comprising SEQ ID NO:
• 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO:
• 10 to SEQ ID NO:
• 58, a polypeptide analog comprising two to fifty units of SEQ ID NO:
• 5, a polypeptide analog comprising two to ten units of SEQ ID NO:
• 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO:
• 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, a polypeptide analog having at least 70% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5, and a polypeptide analog having at least 50% of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO:
• 5 and mixture(s) thereof for the manufacture of a medicament for the therapeutic treatment of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia (BPH) or a disease characterized by elevated levels of FSH.